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To the Editor: We read with interest the article by 
Chochua et al. from the Centers for Disease Control and 
Prevention (1). We appreciate that the authors cited our 
recent publication on the same topic from 8 children’s 
hospitals across the United States (2). Our study encom-
passed pneumococcal serotype 35B invasive and non-
invasive infections, spanning more than 2 decades. We 
believe, however, that their reference to our study needs 
some clarification. We did not report that clonal complex 
(CC) 156 was the major contributor to antimicrobial re-
sistance among serotype 35B isolates, as stated by Cho-
chua et al. We reported a predominance (69.2%) of 35B 
sequence type (ST) 558 among invasive isolates across 
the entire study period (before and after introduction of 
the 13-valent pneumococcal conjugate vaccine [PCV13]); 
95% of the ST558 isolates were penicillin nonsusceptible. 
We noted that clonal expansion of ST558 was the major 
contributor to the increase in prevalence of serotype 35B, 
as did Chochua et al. Furthermore, we observed the emer-
gence of 35B-CC156 after introduction of PCV13 and 
noted that 35B-CC156 isolates were multidrug-resistant 
(penicillin nonsusceptibility plus resistance to >2 non– 
β-lactam antimicrobial drugs), similar to previous ob-
servations of CC156 associated with other pneumococ-
cal polysaccharide capsules (e.g., serotypes 9V and 14). 
Thus, the increase in multidrug resistance among serotype 
35B isolates in the post-PCV13 era was strongly associ-
ated with the emergence of CC156.
Our conclusion that both clonal expansion and diver-
sification had occurred in the post-PCV13 era is validated 
by the results of Chochua et al. During 2015–2016, we ob-
served no further increase in serotype 35B. We agree with 
Chochua et al. that the emergence of serotype 35B is of 
concern and the development of a new generation pneumo-
coccal vaccine is necessary. We will continue to monitor 
and report data regarding ongoing changes in pneumococ-
ci; although our study is not population based, we believe it 
provides reliable data that are useful for clinical, epidemio-
logic, and vaccine-related considerations.
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